Although the biomarkers assessed (albumin, CRP, BuChE, PON1, and haptoglobin) exhibit relatively low intra-individual variability, a single measurement does not fully capture the dynamic nature of inflammatory, oxidative, and metabolic processes that evolve throughout ALS disease progression. The gene discussed is PON1; the disease is amyotrophic lateral sclerosis.